Why CleanSpark, Inc. (CLSK) Crashed on Monday
We recently published an article titled . In this article, we are going to take a look at where CleanSpark, Inc. (NASDAQ:CLSK) stands against the other stocks.
A lackluster trading persisted on the stock market on Monday, with Wall Street's major indices finishing mixed, as investors continued to digest and reposition portfolios ahead of more corporate earnings results.
Among the bellwether indices, only the Nasdaq finished in the red, dropping 0.10 percent. In contrast, the Dow Jones grew by 0.28 percent, and the S&P 500 inched up by 0.06 percent.
Meanwhile, 10 companies defied a predominantly optimistic market.
To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume.
A hall of server racks, illuminated by blue LED lights and humming with energy.
CleanSpark, Inc. (NASDAQ:CLSK) tumbled by 4.88 percent on Monday to end at $8.57 apiece amid the lack of catalyst to spark buying appetite, while investors repositioned portfolios ahead of the release of its second quarter earnings performance.
Based on its historical earnings reporting dates, CleanSpark, Inc. (NASDAQ:CLSK) is set to announce its results in the second week of May 2025.
CleanSpark, Inc. (NASDAQ:CLSK) is a US-based Bitcoin mining company that owns and operates data centers that primarily run on low-carbon power.
In recent news, CleanSpark, Inc. (NASDAQ:CLSK) progressed with its plan for the establishment of a new data center in Mountain City after securing the backing from the Mountain City Planning Board.
If approved, the facility is expected to commence operations within two months.
As of last month, CleanSpark, Inc. (NASDAQ:CLSK) said it was able to mine 706 Bitcoins, pushing its ownership to a total of 11,869.
Meanwhile, the company said it sold 14.23 Bitcoins during the period at an average price of approximately $87,742 apiece.
Overall CLSK ranks 3rd on our list of the worst performing stocks on Monday. While we acknowledge the potential of CLSK as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than CLSK but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: and .
Disclosure: None. This article is originally published at .
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Cresilon Announces International Distribution Agreement for VETIGEL with McCarthy Vet
Revolutionary hemostatic gel for veterinary surgeons available in Canada through leading veterinary supply company NEW YORK, June 16, 2025 /PRNewswire/ -- Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced it has entered into a distribution agreement for VETIGEL® to be sold directly to veterinary surgeons in Canada through McCarthy Vet, a full-service veterinary marketing, supply and distribution company exclusively serving veterinarians in the Canadian animal health industry. VETIGEL, a revolutionary plant-based hemostatic gel that instantly stops and controls bleeding, is now available for veterinarian surgeons across Canada through McCarthy Vet. The agreement with McCarthy Vet, a family-owned and operated company that has exclusively served the Canadian veterinary community for over 60 years, is Cresilon's first veterinary distribution partnership in Canada. "Our partnership with McCarthy Vet will help us provide more veterinary surgeons with an innovative hemostatic gel that significantly improves the standard of care for pets and animals," said VETIGEL National Sales Manager Brittany Boysen. "VETIGEL has been used by thousands of veterinarians around the world and helps veterinary clinics and animal hospitals save time, reduce operating costs, and improve patient outcomes." Since the product's debut in 2021, veterinary surgeons across North America, Europe, and Asia have increasingly used VETIGEL as the fastest and most effective hemostatic agent when treating animals for traumatic wounds and routine and complex surgical procedures, including dental extractions, liver biopsies, tumor and mass removals, cleft palate repairs, and amputations. To date, the plant-based hemostatic gel for veterinary surgeons has been used in more than 60,000 surgical procedures worldwide. As McCarthy Vet expands its portfolio through a new partnership with VETIGEL, the company remains focused on delivering the solutions today's veterinary professionals need most. This collaboration reflects its ongoing promise to bring innovative products to market that offer meaningful clinical value, ease of use, and better outcomes for patients. As a flowable hemostatic gel, VETIGEL offers veterinary surgeons a safe and efficient way to control bleeding across a wide range of surgical procedures and wound geometries. The veterinary hemostatic agent is biocompatible, non-animal derived, and made with an innovative blend of plant polymers that form an instant mechanical barrier to stop bleeding on contact. Once the bleeding is controlled, VETIGEL can be easily removed without disturbing the underlying clot or left in the body to resorb. VETIGEL is supplied in a pre-filled syringe, easy-to-use, and requires no preparation or special storage conditions. For more information about VETIGEL, visit For more information about McCarthy Vet, visit About CresilonCresilon® is a Brooklyn-based biotechnology company that develops, manufactures, and markets hemostatic medical devices utilizing the company's proprietary hydrogel technology. The company's plant-based technology has revolutionized the current standard by stopping bleeding in seconds. The company's current and future product lines target trauma care, biosurgery, and animal health. Cresilon's mission is to save lives. For more information about Cresilon, which was named to Fast Company's annual list of the World's Most Innovative Companies of 2024, ranking No. 1 in the medical devices category, visit About McCarthy VetMcCarthy Veterinary Supplies has proudly served Canadian Veterinarians for over 60 years. McCarthy is committed to bringing clinics the most innovative products, expertise, and service to improve the health of animals, and thereby improve the lives of those who care for them. McCarthy is based in Alberta, Canada, with reps exclusively serving veterinarians in every province from coast to coast. View original content to download multimedia: SOURCE Cresilon
Yahoo
31 minutes ago
- Yahoo
Bracco Imaging and Subtle Medical obtain CE mark for AI-powered MRI software
Italy-based Bracco Imaging and Subtle Medical have obtained an EU CE mark for AiMIFY, a jointly developed software designed to enhance the imaging of contrast MRI brain scans using artificial intelligence (AI). Developed through the application of Bracco's imaging and Subtle's software, clinical evidence has demonstrated that AiMIFY provides contrast enhancement for MRI brain scans up to twice the level typically achieved with a labelled dose of gadolinium-based contrast agents (GBCAs). Consequently, AiMIFY enhances the visualisation of small and poorly enhanced lesions that are critical to the early detection of certain conditions. US-based Subtle Medical's chief product officer, Ajit Shankaranarayanan, points out that in achieving imaging enhancements in contrast MRI scans, whereby a contrast agent is administered to a patient before an MRI is undertaken, the software requires no adjustments to these standard practices. According to the companies, validation data for AiMIFY, which was granted software as a medical device (SaMD) clearance from the US Food and Drug Administration (FDA) in October 2024, has demonstrated the technology's efficacy across diverse patient demographics, pathologies, lesion sizes, scanner vendors, MRI sequences, and acquisition orientations. Radiology platform leader at Bracco Imaging, Sascha Daeuber commented: 'With the CE Mark for AiMIFY, we're taking the next step in our shared mission to deliver innovative, AI-powered solutions that enhance diagnostic precision and support radiologists and patients worldwide." Bracco and Subtle Medical stated that they will now initiate commercialisation activities for AiMIFY in select European markets, with a phased commercial rollout expected between late 2025 and early 2026. According to a 2023 report by GlobalData, the use of AI across healthcare is burgeoning, with the market forecast to reach a valuation of around $19bn by 2027. Radiology has emerged as one of the most common areas in which AI is being applied – as a means to drive efficiencies and alleviate clinician burnout. In a recent report by KPMG on AI's impact on healthcare, 86% of healthcare professionals expressed their belief that AI adoption would give their organisation a competitive edge over those who did not. "Bracco Imaging and Subtle Medical obtain CE mark for AI-powered MRI software" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
32 minutes ago
- Yahoo
Commerce Bancshares to buy Florida peer FineMark in $585 million deal
(Reuters) -U.S. regional bank Commerce Bancshares has agreed to acquire rival FineMark Holdings in an all-stock deal valued at $585 million, the companies said on Monday. Consolidation among U.S. banks is expected to heighten as rising technology and compliance costs push lenders to scale via mergers and acquisitions. A lighter regulatory touch under the Trump administration is also fueling prospects of bigger deals. Shareholders will receive 0.69 shares of Commerce for each share of FineMark they hold. As of the market close on Friday, the terms represent a 54.7% premium for FineMark shareholders, according to Reuters calculations. Founded in 2007, Florida-based FineMark offers wide-ranging banking and non-banking services to clients through 13 offices in Florida, Arizona and South Carolina. The bank had $4 billion in assets, as of March 31. The company's trust and investment business holds assets under administration of around $7.7 billion. "Together, with over $36 billion in assets and over $82 billion in wealth assets under administration, we are poised to accelerate growth, expand our reach, and deliver even greater value,," said John Kemper, CEO of Kansas City, Missouri-based Commerce Bancshares. Keefe, Bruyette & Woods acted as financial adviser to Commerce Bancshares, while Piper Sandler advised FineMark. The transaction is expected to close on January 1.
